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Background. MicroRNAs are a type of small noncoding RNA molecules that have been shown to control gene expression in
eukaryotes. Aberrant expression and alteration of miRNAs may be responsible for human diseases including cancer. An miR16-1
(C > T) + 7 gene mutation has been previously found in familial chronic lymphocytic leukemia patients, one of which reported
a family history of breast cancer. miR16-1 regulates the expression of bcl-2, which is important in retinoblastoma, and is located
in a genomic region that is frequently lost in nasopharyngeal and hepatocellular carcinomas (HCCs). Therefore, miR16-1 may
be potentially important in the etiology of several solid tumors. To understand the power of the miR16-1 (C > T) + 7 mutation
as a prognostic and diagnostic risk factor, we investigated the mutation in patients with seven diﬀerent types of cancer including
188 with breast, 102 with ovarian, and 22 nasopharyngeal carcinomas, 96 HCC, 872 chronic myeloid leukemia (CML), 39 chronic
lymphocytic leukemia (CLL), and 46 retinoblastoma cases from three diﬀerent ethnic groups and of hereditary and sporadic
etiology. Methods.5  Nuclease TaqMan SNP genotyping assay was used to detect the miR16-1 gene C > T substitution. Results.T h e
miR16-1 (C > T) + 7 substitution was not detected in any of the groups studied. Conclusions. Considering the large scale of our
study, the representation of diﬀerent ethnicities and levels of hereditary risk, we conclude that the miR-16-1 (C > T) + 7 mutation
is not a good diagnostic or prognostic indicator of risk for the cancers tested.
Copyright © 2009 Hulya Yazici et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
MicroRNAs are a group of small noncoding RNA (ncRNA)
molecules that have been identiﬁed in many organisms
[1, 2] and shown to regulate the expression of genes in
a variety of eukaryotic systems. A recent analysis of the
genomic location of human microRNA genes suggested
that 50% are located in cancer-associated genomic regions
or fragile sites [3, 4]. Recently, Calin et al. identiﬁed
mutationsinsixmicroRNAgenes(miR-16-1,miR-27b,miR-
29b2/29a, miR122a, miR-187, miR-206) in patients with
Chronic Lymphocytic Leukemia (CLL) [5]; none of these
mutations were found in a set of 160 individuals without
cancer (P<. 0001) [5]. One germline mutation, miR16-1
C > T + 7, resulted in reduced expression of miR-16-1 both
in vitro and in vivo. Since miR16-1 induces apoptosis by
repressing bcl-2, a decrease in miR16-1 will result in bcl-
2 overexpression, which is a common feature in CLL [6].
Previous data indicated that miR16-1 and miR15a behave
as tumor suppressors in CLL. The combination of loss of
heterozygosity plus a germline mutation in this region is
consistent with the Knudson Model of inactivation of a
tumor suppressor gene. Thus, the presence of deleterious
mutations in miR-15a and miR-16-1 suggests that this new
class of RNAs may play a signiﬁcant role in many sporadic
and hereditary cancers. miR-15a and miR-16-1 are located
onchromosome13q14.3closetoBRCA2,whichisfrequently
mutated in hereditary breast and ovarian cancers, and Rb,2 Journal of Oncology
Table 1: Distribution of cancer patients in the study.
Type of cancer Number of
patients
Number of
specimen
Source of DNA Nationality of
patients Tissue Blood
Solid Tumors Breast Cancer (sporadic) 108 148 108 40 Turkish§
Breast Cancer (hereditary) 80 80 NA 80 American∗
Ovarian Cancer (sporadic) 23 46 23 23 Turkish§
Ovarian Cancer
(hereditary) 79 79 NA 79 Turkish§
HCC (Sporadic) 96 96 96 NA Chinese
Nasopharyngeal
Carcinoma (sporadic) 22 22 22 ND Turkish§
Leukemias CML 872 872 — 872 Turkish§
CLL 39 39 39 Turkish§
Childhood Cancers Retinoblastoma (Sporadic ) 46 46 46 ND Turkish§
Total 1365 1428 295 1134
∗42 Caucasian, 34 Hispanic, 2 Asian, 2 other, §Caucausian
NA; material not avaible, ND; not detected.
w h i c hi sd e l e t e do rm u t a t e di nr e t i n o b l a s t o m aa n ds a r c o m a s .
In fact, one of the individuals with CLL in which the
mutation was identiﬁed reported a family history of breast
cancer. Perhaps the mutation in miR16-1 can interact with
inactivation of miR16-1 to modify the clinical phenotype
[7]. Several cancers, including nasopharyngeal and HCC,
have a high frequency of LOH near miR15a/miR16-1. Shao
et al. found that 78% of nasopharyngeal tumors had LOH
at 13q [8]; another group found that the highest frequency
of LOH in nasopharyngeal cancer was at loci D13S133
(53.6%) on 13q14.3 [9]. In HCC, LOH at subchromosomal
regions 13q12.3-14.1 and 13q32 was signiﬁcantly associated
with advanced tumor stage and larger tumor size [10].
Further, homozygous deletion of 13q12.11 was signiﬁcantly
associated with early onset HCC [11]. Finally, since there
are no data on the miR 16 C > T+7m u t a t i o ni nC M L ,
these patients were included in this study. We genotyped
1428 biological samples including tissue and blood DNA
from a total of 1365 patients diagnosed with diﬀerent types
of cancer, including breast and ovarian cancers, HCC, CML,
CLL nasopharyngeal carcinoma, and retinoblastoma using a
TaqMan assay for the miR16-1 gene C > T substitution.
2.MaterialsandMethods
The study population consisted of 188 breast carcinomas
(108 cases without and 80 cases with a family history of
breast and ovarian cancer), 102 ovarian cancer (23 cases
without and 79 cases with a family history of breast or
ovarian cancer), 96 HCC, 22 nasopharyngeal carcinoma,
872 CML, 39 CLL, and 46 sporadic retinoblastoma cases.
For some sporadic breast and ovarian cases both blood
and tissue DNA was tested (40 of 108 sporadic breast and
23 of 23 sporadic ovarian cancer patients) for a total of
1428 specimens belonging to 1365 cases (Table 1). The HCC
cases were recruited between December, 1998 and July, 2005
from an HCC endemic region in southern China. Tissue
specimens from ovarian, and nasopharyngeal carcinomas
and retinoblastoma patients and blood samples from CML
and CLL patients were collected from Turkish patients in the
Oncology Institute, University of Istanbul between 1991 and
2000. Samples from breast carcinoma cases were collected in
two independent studies; patients were of Turkish (Oncol-
ogy Institute) and American origin (Columbia University
MedicalCenter)andcollectedbetween1991–2005and1995–
2005, respectively. Analysis of the miR16-1 gene C > T
substitution was performed using the 5  nuclease TaqMan
SNP genotyping assay. TaqMan primers and probes were
designed by Applied Biosystems Inc. (ABI, Foster City, Calif,
USA) with sequence data from the Sanger Center Web-
site (http://www.sanger.ac.uk/Software/Rfam/mirna/). The
probes were labeled with either FAM or VIC; allele a speciﬁc
hybridization and degradation allowed for discrimination of
the mutated versus the wild type sequence. As a control,
two 100bp synthetic oligonucleotides (Invitrogen, Carisbad,
Calif, USA) corresponding to either the wild type or mutant
sequence were used to verify the speciﬁcity of the probes.
The reactions were prepared as follows: 10µLo fT a q M a n
Universal Master Mix, in 20µL ﬁnal reaction volumes, with
20ng DNA, 0.2µL TaqMan SNP Genotyping Assay Mix
(80X) resulting in a ﬁnalconcentrationof 900nmol/L for the
primers,and200nmol/Loftheprobes.Thermalcyclingcon-
ditions were 95◦C for 10 minutes, and then 40 cycles of 95◦C
for 15 seconds and 60◦C for 1 minute. Thermal cycling was
performed on an ABI-Realtime 7500 system using the abso-
lute quantitation program standard with ABI SDS software
version 1.2.3. Each 96-well plate contained 92 test samples
and four reaction controls, including nontemplate, synthetic
oligonucleotide homozygous for the C, or T allele and
synthetic oligonucleotides combined tomake aheterozygote.
3. Results and Discussion
MicroRNAs can be involved in cancer initiation and pro-
gression and their expression proﬁling can be exploited
for the classiﬁcation, diagnosis, and prognosis of humanJournal of Oncology 3
malignancies. In addition, germline and somatic mutations
in several miRNAs seem to contribute to cancer pre-
disposition and progression. To understand this, we searched
1428 biological specimens including tissue and blood DNA
from a total of 1365 patients diagnosed with diﬀerent types
of cancer, including breast and ovarian cancers, HCC, CML,
CLL, nasopharyngeal carcinoma and retinoblastoma for the
miR16-1 (C > T) + 7 mutation.
We did not detect any mutations in the 1428 samples
from 1365 cases analyzed. Our study encompassed a wide
rangeofcancertypesincludingsolidtumors(breast,ovarian,
nasopharyngeal and HCC), leukemias (CML, CLL) and a
childhood cancer (retinoblastoma). We also analyzed DNA
samples from individuals representing several ethnicities
including American (primarily Caucasian), Chinese and
Turkish, and in some cases’ (breast and ovarian) individuals
with and without a family history of cancer.
The germline mutation found in the miR-16-1 and
miR15a primary precursor caused low levels of microRNA
expression in vitro and in vivo and was associated with
deletion of the normal allele in CLL [5]. However, results
havenotbeenconsistent[12].MicroRNAsmiR-15aandmiR-
16-1 are located in the region of a deletion at 13q13.4. This
region is frequently deleted or downregulated in CLL cells
and the miR16-1 (C > T) + 7 germ line mutation was
found in one of the familial CLL patients who also had a
family history of breast cancer [5]. BRCA2 and Rb,m u t a t e d
in hereditary breast and ovarian cancer and retinoblastoma
patients, are relatively close to the miR16-1 gene,a n ds o m e
tumors such as nasopharyngeal and HCC have some LOH in
the region suggesting that the miR16-1 C > T+7m u t a t i o n
may be important in other cancers. A miR16-1 mutation in
the 3  ﬂanking region was recently identiﬁed in NZB mice
that serve as a model for human CLL, further supporting
a unique role for miR16-1 in CLL [13], and it was shown
that the C > T substitution on miR16-1 gene aﬀects the
levelofexpressionofmaturemicroRNAs[5].Thepercentage
of mutation in CLL was 2.6% in the study of Calin et al.
and one of the patients was a hereditary CLL case and had
a familial history of breast cancer history. Moreover, we did
not identiﬁed any miR16-1 C > T+7m u t a t i o ni no u rC L L
subgroup of cases who had no hereditary CLL and cancer
history in their family. Our results for miR16-1 C > T+7
mutation in CLL are concordant with the study of Borkhardt
et al. The frequency of mutation can be diﬀerent for a
particular population and hereditary background of patients
and ethnicity can aﬀect the results.
Our results suggest that mutation of miRNA 16-1 is
not informative as a prognostic and diagnostic risk factor
for the diﬀerent types of cancers we studied. miR16-1 C >
T + 7 mutation may be important in other solid tumors
such as colorectal and lung cancer and especially B-cell Non
Hodgkin lymphoma which arise from the same progenitor
branch of cell lineage as CLL.
4. Conclusions
In our large scale study with representation from diﬀerent
ethnicities and with various levels of hereditary risk, we
did not identify any cases with the miR-16-1 (C > T) + 7
mutation in any of the cancers tested. However, we tested
for the presence of only one type of mutation in one
miRNA gene. Many miRNA genes have been investigated
for diﬀerent type of mutations in diﬀerent type of cancer.
Therefore, further research is necessary to determine the
importance of the distribution of miRNA mutations in
carcinogenesis.
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